Advancing Equity: Pediatric Atopic Dermatitis Management in Managed Care
- Release Date: February 15, 2025
- Expiration Date: August 31, 2026
- Estimated Time to Complete Activity: 1.0 hour
- Compatible with all modern browsers and mobile devices
 |
Expert Faculty
California AMCP Affiliate Presenters |
|
Midwest AMCP Affiliate Presenters |
|
Target Audience
This activity is designed to meet the educational needs of AMCP affiliate members in the roles of pharmacy directors, clinical pharmacists, specialty pharmacists, medical directors, registered nurses, quality directors, and other pharmacists and physicians affiliated with various MCOs, health systems, and other payer organizations.
Statement of Need/Program Overview
Enhanced knowledge is needed of the overall burden of AD in children and recommended treatments that can empower managed care, specialty pharmacy, and other payer decision makers to implement health care benefit policy strategies that will enhance optimal treatment outcomes. In addition, effective communication and collaboration is needed between payer professionals and pediatric dermatologists for resolving coverage issues, addressing reimbursement concerns, and streamlining administrative processes. Lastly, to address racial and ethnic disparities in children with AD, target audience members need to enact coverage criteria that takes into consideration there are different presentations of AD across skin tones and different levels of access to specialized care.
Educational Objectives
After completing this activity, the participant should be better able to:
- Examine the experiences of pediatric patients and their caregivers in managing moderate-to-severe atopic dermatitis (AD)
- Outline evidence-based treatment recommendations in pediatric AD
- Assess regional opportunities within managed care to address factors that contribute to healthcare disparities in the care and treatment of pediatric patients with AD
- Analyze regional trends that inform strategic decision-making to improve managed care policies for AD treatments within respective organizations
- Explore collaborative strategies for the implementation of equitable drug coverage policies for pediatric AD treatments
Accreditation Information
 |
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
|
Physician Continuing Medical Education
PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
PACE designates this continuing education activity for 1.0 contact hour (0.10 CEU) of the Accreditation Council for Pharmacy Education.
UAN: JA4008073-9999-25-066-H01-P
Type of Activity: Application
For Pharmacists: Upon successfully completing the activity evaluation form your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.
Continuing Nursing Credit
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
DISCLOSURES
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
| Name of Faculty or Presenter |
Reported Financial Relationship |
| Lawrence Eichenfield, MD |
Consultant/Advisor/Speaker: Dermavant, Forte, Galderma, Incyte, Leo, Lilly, Otsuka, Pfizer, Regeneron, Sanofi, UCB
Researcher: Castle Biosciences, Dermavant, Galderma, Incyte, Pfizer
Stock Options: Forte |
| Sydney Leibel, MD, MPH |
Consultant/Advisor/Speaker: Regeneron, AstraZeneca
Researcher: AstraZeneca, OM Pharma |
| Carolyn Szigethy, PharmD |
Nothing to disclose. |
| Michele Guadalupe |
Nothing to disclose. |
| Denise Wolff, PharmD |
Nothing to disclose. |
| Sheilagh Maguiness, MD |
Advisory Participant – Regeneron/Sanofi
Co-Founder – Stryke Club |
| Susan Wescott, RPh, MBA |
Employee of Mayo Clinic; however, salary is funded by Alluma. |
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
FEE INFORMATION
There is no fee for this educational activity.
